MAKE THE SCIENCE WORK FOR YOU.

One of Regenative Labs’ goals is to give patients with articular cartilage defects more options in their quest to restore their health. Options exist for those addressing damaged tissue involving attachment points or surrounding soft tissue as well. Let Regenative Labs demonstrate how Wharton’s jelly for Connective Tissue Supplementation can be used to repair or replace the damaged tissue with new healthy connective tissue.

CRYOTEXT

CryoText is our most concentrated, non-coded Wharton's Jelly or human umbilical cord product that is rich in cytokines, growth factors and scaffolding proteins. It acts as a replacement tissue that is intended to replace missing or damaged connective tissue.

Possible Use Cases

Structural support for soft tissues and joints

SECRETEXT

SecreText is our newest dose form of Wharton's Jelly intended for smaller defects. Its tissue size is best suited for aesthetic applications where volume is needed to cushion or support the affected area.

Possible Use Cases

  • Aesthetics
  • Women’s Health
  • Men’s Health

PROTEXT

Regenative Labs Wharton’s jelly allografts are regulated under section 361 of the Public Health Service Act (PHS) and 21 CFR Part 1271. This product is coded Q4246.

Possible Use Cases

Structural support for soft tissues and joints

AMNIOTEXT

AmnioText is a sterile, dehydrated human amniotic membrane allograft, intended for homologous use to cover and protect the recipient's tissues. AmnioText™ is minimally manipulated and processed to preserve the original relevant characteristics relating to its utility as a barrier.

Regenative Labs’ resources are divided into the following categories:

Discovery icon - magnifying glass

Discover

Discover our catalogue of applications showcasing how Regenative Labs’ proprietary products can be used.

View All Applications
arrow
Explore icon - DNA and magnifying glass

EXPLORE

Explore the detailed descriptions of our products, their make-up and development through our state-of-the-art process and to identify which products are best suited for your patients’ unique needs.

View all products
arrow

Commitment to Quality and Transparency

Regenative Labs is a leader in the field of regenerative medicine. Our commitment to quality and transparency is demonstrated by collecting data from patient outcomes and analyzing it for statistical significance, ensuring physicians make the most informed decision to facilitate the best possible outcomes for their patients.

From our retrospective data repository, you will witness improvements beginning at the 30-day mark.

LEARN About Wharton’s Jelly

About Wharton’s Jelly

Advances in regenerative medicine have increased significantly throughout the past decade. Wharton’s Jelly (WJ) was initially characterized in 1656 by Thomas Wharton. Since its initial discovery, there has been significant interest in the use of WJ in regenerative medicine applications. Located between the blood vessels of the umbilical cord and the amniotic epithelium, WJ spans the entire length of the umbilical cord, providing protection, cushioning, and structural support. Initial research centered on WJ as a cellular product, dependent on the metabolic activity of living cells to exert its primary function. However, current research demonstrates that WJ exerts an effect independent of any cellular activity. Initially classified as a mucoid connective tissue, we now know that WJ functions as an ideal system to transplant chemokine and growth factors, in addition to providing a biomechanical microarchitecture for collagen extracellular matrix formation in collagen-based defects.

CITATIONS:

1. Kim DW, Staples M, Shinozuka K, Pantcheva P, Kang SD, Borlongan CV. Wharton’s jellyderived mesenchymal stem cells: phenotypic characterization and optimizing their therapeutic potential for clinical applications. Int J Mol Sci. 2013 May 31;14(6):11692-712. doi: 10.3390/ijms140611692. PMID: 23727936; PMCID: PMC3709752.

2. Gupta A, El-Amin SF 3rd, Levy HJ, Sze-Tu R, Ibim SE, Maffulli N. Umbilical cordderived Wharton’s jelly for regenerative medicine applications. J Orthop Surg Res. 2020 Feb 13;15(1):49. doi: 10.1186/s13018-020-1553-7. PMID: 32054483; PMCID: PMC7017504.

3. Deus IA, Mano JF, Custódio CA. Perinatal tissues and cells in tissue engineering and regenerative medicine. Acta Biomater. 2020 Jul 1;110:1-14. doi: 10.1016/j. actbio.2020.04.035. Epub 2020 May 14. PMID: 32418650.

4. Jadalannagari S, Converse G, McFall C, Buse E, Filla M, Villar MT, Artigues A, MellotAJ, Wang J, Detamore MS, Hopkins RA, Aljitawi OS. Decellularized Wharton’s Jelly from human umbilical cord as a novel 3D scaffolding material for tissue engineering applications. PLoS One. 2017 Feb 21;12(2):e0172098. doi: 10.1371/journal. pone.0172098. Erratum in: PLoS One. 2017 Mar 7;12 (3):e0173827. PMID: 28222169; PMCID: PMC5319682.

Advantages of Wharton’s Jelly

This connective tissue contains high amounts of extracellular matrix components including collagen types I, III, and V, elastin, and fibronectin that provide a natural scaffold to facilitate cellular adhesion (1, 2). Wharton’s jelly mainly provides cushioning and structural support to the umbilical cord but also contains a natural source of long-chain hyaluronic acid and numerous cytokines and growth factors. Studies have described placental tissues to be “immune privileged” as they rarely evoke an immune response in the body, reducing the risk of adverse reaction (4).

CITATIONS:

1. Kim DW, Staples M, Shinozuka K, Pantcheva P, Kang SD, Borlongan CV. Wharton’s jellyderived mesenchymal stem cells: phenotypic characterization and optimizing their therapeutic potential for clinical applications. Int J Mol Sci. 2013 May 31;14(6):11692-712. doi: 10.3390/ijms140611692. PMID: 23727936; PMCID: PMC3709752.

2. Gupta A, El-Amin SF 3rd, Levy HJ, Sze-Tu R, Ibim SE, Maffulli N. Umbilical cordderived Wharton’s jelly for regenerative medicine applications. J Orthop Surg Res. 2020 Feb 13;15(1):49. doi: 10.1186/s13018-020-1553-7. PMID: 32054483; PMCID: PMC7017504.

3. Jadalannagari S, Converse G, McFall C, Buse E, Filla M, Villar MT, Artigues A, MellotAJ, Wang J, Detamore MS, Hopkins RA, Aljitawi OS. Decellularized Wharton’s Jelly from human umbilical cord as a novel 3D scaffolding material for tissue engineering applications. PLoS One. 2017 Feb 21;12(2):e0172098. doi: 10.1371/journal. pone.0172098. Erratum in: PLoS One. 2017 Mar 7;12 (3):e0173827. PMID: 28222169; PMCID: PMC5319682.

About Wharton’s Jelly

Advances in regenerative medicine have increased significantly throughout the past decade. Wharton’s Jelly (WJ) was initially characterized in 1656 by Thomas Wharton[1]. Since its initial discovery, there has been significant interest in the use of WJ in regenerative medicine applications[2]. Located between the blood vessels of the umbilical cord and the amniotic epithelium, WJ spans the entire length of the umbilical cord, providing protection, cushioning, and structural support [2,3]. Initial research centered on WJ as a cellular product, dependent on the metabolic activity of living cells to exert its primary function[3]. However, current research demonstrates that WJ exerts an effect independent of any cellular activity[3]. Initially classified as a mucoid connective tissue, we now know that WJ functions as an ideal system to transplant chemokine and growth factors, in addition to providing a biomechanical microarchitecture for collagen extracellular matrix formation in collagen-based defects[4].

CITATIONS:

1. Kim DW, Staples M, Shinozuka K, Pantcheva P, Kang SD, Borlongan CV. Wharton’s jellyderived mesenchymal stem cells: phenotypic characterization and optimizing their therapeutic potential for clinical applications. Int J Mol Sci. 2013 May 31;14(6):11692-712. doi: 10.3390/ijms140611692. PMID: 23727936; PMCID: PMC3709752.

2. Gupta A, El-Amin SF 3rd, Levy HJ, Sze-Tu R, Ibim SE, Maffulli N. Umbilical cordderived Wharton’s jelly for regenerative medicine applications. J Orthop Surg Res. 2020 Feb 13;15(1):49. doi: 10.1186/s13018-020-1553-7. PMID: 32054483; PMCID: PMC7017504.

3. Deus IA, Mano JF, Custódio CA. Perinatal tissues and cells in tissue engineering and regenerative medicine. Acta Biomater. 2020 Jul 1;110:1-14. doi: 10.1016/j. actbio.2020.04.035. Epub 2020 May 14. PMID: 32418650.

4. Jadalannagari S, Converse G, McFall C, Buse E, Filla M, Villar MT, Artigues A, MellotAJ, Wang J, Detamore MS, Hopkins RA, Aljitawi OS. Decellularized Wharton’s Jelly from human umbilical cord as a novel 3D scaffolding material for tissue engineering applications. PLoS One. 2017 Feb 21;12(2):e0172098. doi: 10.1371/journal. pone.0172098. Erratum in: PLoS One. 2017 Mar 7;12 (3):e0173827. PMID: 28222169; PMCID: PMC5319682.

Advantages of Wharton’s Jelly

This connective tissue contains high amounts of extracellular matrix components including collagen types I, III, and V, elastin, and fibronectin that provide a natural scaffold to facilitate cellular adhesion [1, 2]. Wharton’s jelly mainly provides cushioning and structural support to the umbilical cord but also contains a natural source of long-chain hyaluronic acid and numerous cytokines and growth factors. Studies have described placental tissues to be “immune privileged” as they rarely evoke an immune response in the body, reducing the risk of adverse reactions [3].

CITATIONS:

1. Kim DW, Staples M, Shinozuka K, Pantcheva P, Kang SD, Borlongan CV. Wharton’s jellyderived mesenchymal stem cells: phenotypic characterization and optimizing their therapeutic potential for clinical applications. Int J Mol Sci. 2013 May 31;14(6):11692-712. doi: 10.3390/ijms140611692. PMID: 23727936; PMCID: PMC3709752.

2. Gupta A, El-Amin SF 3rd, Levy HJ, Sze-Tu R, Ibim SE, Maffulli N. Umbilical cordderived Wharton’s jelly for regenerative medicine applications. J Orthop Surg Res. 2020 Feb 13;15(1):49. doi: 10.1186/s13018-020-1553-7. PMID: 32054483; PMCID: PMC7017504.

3. Jadalannagari S, Converse G, McFall C, Buse E, Filla M, Villar MT, Artigues A, MellotAJ, Wang J, Detamore MS, Hopkins RA, Aljitawi OS. Decellularized Wharton’s Jelly from human umbilical cord as a novel 3D scaffolding material for tissue engineering applications. PLoS One. 2017 Feb 21;12(2):e0172098. doi: 10.1371/journal. pone.0172098. Erratum in: PLoS One. 2017 Mar 7;12 (3):e0173827. PMID: 28222169; PMCID: PMC5319682.

CryoText Product Information

For more information about our Cryotext product, visit the link below.

Pricing and PLACING AN order

For pricing or to place an order, login or setup an account to get immediate access to our MEDNGINE platform.

DON’t HESITATE TO REACH OUT.

If you have any further questions, please contact us. We look forward to speaking with you!

CODE LIST

Download the ICD-10 Code List to Identify Other Potential Use Sites.